Neumora Therapeutics Inc Quick Ratio (NMRA) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Neumora Therapeutics Inc   (NASDAQ: NMRA)

Neumora Therapeutics Inc 's Quick Ratio

NMRA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.34 a new company low.

Within Biotechnology & Pharmaceuticals industry 105 other companies have achieved higher Quick Ratio than Neumora Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 413 to 1570.

Explain Quick Ratio?
How much Cash & cash equivalents NMRA´s has?
What are NMRA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NMRA Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 318.62 % 9.15 % 7.63 % -19.57 % -9.63 %
Y / Y Cash & cash equivalent Change -46.3 % -41.02 % -40.66 % -49.74 % -41.45 %
Quick Ratio MRQ 1.34 4.93 5.67 6.72 10.41
NMRA's Total Ranking # 1570 # 413 # 526 # 412 # 243
Seq. Current Liabilities Change 193.31 % -7.28 % 25.99 % 22.18 % -23.52 %
Seq. Cash & cash equivalent Change -20.56 % -19.43 % 6.42 % -21.17 % -12.74 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 106
Healthcare Sector # 579
Overall Market # 1570


Quick Ratio Statistics
High Average Low
18.08 10.92 1.34
(Dec 31 2023)   (Jun 30 2026)




Financial Statements
Neumora Therapeutics Inc 's Current Liabilities $ 87 Millions Visit NMRA's Balance sheet
Neumora Therapeutics Inc 's Cash & cash equivalent $ 117 Millions Visit NMRA's Balance sheet
Source of NMRA's Sales Visit NMRA's Sales by Geography


Cumulative Neumora Therapeutics Inc 's Quick Ratio

NMRA's Quick Ratio for the trailling 12 Months

NMRA Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 59.31 % -3.26 % -3.15 % -0.91 % 7.73 %
Y / Y Cash & cash equivalent TTM Growth -44.62 % -43.4 % -43.11 % -40.49 % -36.53 %
Quick Ratio TTM 3.53 6.63 7.75 9.13 10.16
Total Ranking TTM # 3626 # 1996 # 2663 # 2680 # 2321
Seq. Current Liabilities TTM Growth 61.41 % 2.36 % 2.2 % -5.65 % -1.99 %
Seq. Cash & cash equivalent TTM Growth -14.02 % -12.46 % -13.22 % -15.22 % -12.13 %

Quick ratio ranking by company, industry and sector >> Back to NMRA Financial Strength Comparisons >> Go to Compare NMRA Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $87.48 millions, cumulative Quick Ratio decreased to 3.53 below the Neumora Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 137 other companies have achieved higher Quick Ratio than Neumora Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 1996 to 3626.

Explain Quick Ratio?
How much Cash & cash equivalents NMRA´s has?
What are NMRA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 138
Healthcare Sector # 860
Within the Market # 3626


trailing twelve months Quick Ratio Statistics
High Average Low
17.24 10.6 5.32
(Jun 30 2024)   (Jun 30 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Entera Bio Ltd   3.50 $ 11.309  Millions$ 3.235  Millions
Exozymes Inc   3.49 $ 5.653  Millions$ 1.618  Millions
Acumen Pharmaceuticals Inc   3.44 $ 160.954  Millions$ 46.848  Millions
Century Therapeutics inc   3.29 $ 49.642  Millions$ 15.068  Millions
Adma Biologics Inc   3.26 $ 136.020  Millions$ 41.690  Millions
Tscan Therapeutics Inc   3.23 $ 100.156  Millions$ 30.964  Millions
Sutro Biopharma Inc   3.11 $ 164.346  Millions$ 52.898  Millions
Editas Medicine Inc   3.09 $ 211.645  Millions$ 68.434  Millions
Autolus Therapeutics Plc  2.93 $ 201.630  Millions$ 68.790  Millions
Moderna Inc   2.73 $ 6,910.000  Millions$ 2,534.000  Millions
Sana Biotechnology Inc   2.59 $ 320.990  Millions$ 123.752  Millions
Tarsus Pharmaceuticals Inc   2.56 $ 449.690  Millions$ 175.753  Millions
Meiragtx Holdings Plc  2.46 $ 143.166  Millions$ 58.096  Millions
Kodiak Sciences Inc   2.39 $ 125.903  Millions$ 52.770  Millions
Exelixis Inc   2.32 $ 839.385  Millions$ 361.927  Millions
Precision Biosciences Inc  2.19 $ 87.549  Millions$ 39.886  Millions
Novavax inc   2.18 $ 719.340  Millions$ 330.574  Millions
Regenxbio Inc   2.11 $ 174.530  Millions$ 82.621  Millions
Biocardia Inc   2.00 $ 4.117  Millions$ 2.055  Millions
Kymera Therapeutics Inc   1.75 $ 124.477  Millions$ 71.326  Millions
Biocryst Pharmaceuticals Inc   1.69 $ 353.279  Millions$ 208.846  Millions
Coherus Oncology inc   1.69 $ 127.683  Millions$ 75.510  Millions
Bio techne Corp  1.62 $ 264.712  Millions$ 163.700  Millions
Atara Biotherapeutics Inc   1.45 $ 9.900  Millions$ 6.847  Millions
Twist Bioscience Corporation  1.39 $ 166.839  Millions$ 120.255  Millions
Neumora Therapeutics Inc   1.34 $ 116.834  Millions$ 87.478  Millions
Calidi Biotherapeutics Inc   1.33 $ 4.290  Millions$ 3.237  Millions
Passage Bio Inc   1.17 $ 24.155  Millions$ 20.719  Millions
Mink Therapeutics Inc   1.16 $ 8.807  Millions$ 7.569  Millions
Amgen Inc   1.07 $ 27,404.000  Millions$ 25,502.000  Millions

Date modified: 2026-09-26T07:42:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.